Pharmacogenomics and Psychiatric Clinical Care

J Psychosoc Nurs Ment Health Serv. 2018 Jan 1;56(1):22-31. doi: 10.3928/02793695-20170928-01. Epub 2017 Oct 9.

Abstract

Approximately one in five individuals in the United States experiences mental health issues in any given year, and these disorders are consistently among the leading causes of years lived with disability. Unfortunately, many mental illnesses are lifelong conditions that require medication and therapy to improve quality of life, yet clinical trial data show that many patients fail to achieve remission or require several pharmacological interventions prior to remission. These results indicate a need to address the variability among patients in their response to medication, in addition to developing treatment plans tailored to the individual. One approach that may help explain patient variability in response to medication is pharmacogenetic testing. The current review shows the clinical use of pharmacogenetic testing in a small subset of gene variants and how they pertain to psychiatric illness and treatment. Recent evidence suggests that genetic testing for psychiatric illness can improve patient outcomes in addition to decreasing health care costs. [Journal of Psychosocial Nursing and Mental Health Services, 56(1), 22-31.].

MeSH terms

  • Humans
  • Mental Disorders / drug therapy
  • Mental Disorders / genetics*
  • Mental Disorders / therapy
  • Pharmacogenetics*
  • Psychiatric Nursing*
  • Psychotherapy
  • Quality of Life
  • United States